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Background: miRNAs are a class of small non-coding RNA molecules that play an important role in the pathogenesis of
human diseases through negative regulation of gene expression. Although miRNA-10b (miR-10b) has been implicated in
other tumors, its role in non-small cell lung cancer (NSCLC) is still unknown. The aim of the present study was to
investigate the role of miR-10b in NSCLC.
Methods: Expression of miR-10b was analyzed in NSCLC cell line A549 by qRT-PCR. Cell viability was evaluated using
Cell Counting Kit (CCK)-8. Cell migration and invasion were evaluated by wound healing assay and transwell assays. Cell
cycle and apoptosis analyses were performed. Western blotting was used to predicate the target of miR-10b.
Results: The A549 cell line transfected with the miR-10b exhibited significantly increased proliferation, migration, and
invasion capacities when compared with the control cells (P < 0.05). Krüppel-like factor 4 (KLF4) may be indirectly
targeted by miR-10b during the proliferation increasing of A549 cells.
Conclusion: In this study, we found that miR-10b is a tumor enhancer in NSCLC. Thus, miR-10b may represent a
potential therapeutic target for NSCLC intervention.
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Non-small cell lung cancer (NSCLC) is the predominant
form of lung cancer, and accounts for the majority of
cancer deaths worldwide [1]. The prognosis of lung can-
cer is still unfavorable, with a 5-year overall survival rate
of approximately 11%, despite recent advances in clinical
and experimental oncology [2]. Thus, detailed NSCLC de-
velopment and progression research is essential for improv-
ing the diagnosis, prevention, and treatment of this disease.
Recently, an increasing number of reports have shown that
non-coding small RNAs may be involved in NSCLC patho-
genesis, providing new insights into disease biology.
The miRNAs are endogenous small non-coding RNAs
of 21 to 24 nucleotides that regulate gene expression by
base pairing with target mRNAs in the 3′-untranslated
region (3′-UTR), leading to mRNA cleavage or transla-
tional repression [3,4]. There are now more than 700
human miRNAs annotated in the miRBase database* Correspondence: gq_zhang2@126.com
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reproduction in any medium, provided the or(University of Manchester, Manchester, UK), and it has
been predicted that in total there are more than 1,000
human miRNAs [5,6]. It is estimated that approximately
one third to one half of human genes are regulated by
miRNAs, and each miRNA is predicted to target several
hundred transcripts, making miRNAs one of the largest
families of gene regulators. Dysregulation of miRNAs
may lead to alterations in cellular differentiation, prolif-
eration, and apoptotic processes of cancer [7,8]. Indeed,
deregulation of miRNAs is closely associated with tumor
initiation, promotion, and progression through the regula-
tion of key oncogenes or tumor suppressors [9-13]. Thus,
understanding the biological consequences of miRNA dys-
regulation and identifying miRNA targets are critical for
diagnosis, prevention, and treatment of cancer.
miRNA-10b (miR-10b) has been reported to play a role
in the invasion and metastasis of cancer. miR-10b is highly
expressed in metastatic breast cancer cell lines and meta-
static breast tumors of patients. miR-10b upregulation in-
hibits the translation of HOXD10, a transcription factor
known for its roles in cell motility, leading to the increas-
ing expression of the prometastatic gene RhoC [14].This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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levels and increases the levels of HOXD10 to inhibit me-
tastasis [15]. MiR-10b expression has subsequently been
shown to correlate with the migration and invasion of hu-
man esophageal cancer cell lines through regulation of
Kruppel-like factor 4 (KLF4) expression [16]. Moreover,
miR-10b is overexpressed in malignant glioma, pancreatic
cancer, and nasopharyngeal carcinoma [17-20]. However,
whether overexpression of miR-10b is involved or not in
NSCLC pathogenesis has not yet been investigated.
In this study, we focused on the expression and roles
of miR-10b in the A549 cell line, and found that
miR-10b promotes the proliferation and invasion of
A549 cells in vitro.
Methods
Cell lines and culture conditions
NSCLC adenocarcinoma cell lines A549 and H1299 were
purchased from the Institute of Biochemistry and Cell
Biology of the Chinese Academy of Sciences (Shanghai,
China). Cells were cultured in RPMI 1640 or medium sup-
plemented with 10% FBS (Gibco, Carlsbad, CA, USA), 100
U/mL penicillin, and 100 mg/mL streptomycin (Invitro-
gen, Carlsbad, CA, USA) in humidified air at 37°C with
5% CO2.
Cell transfection
The miR-10b (sense: 5′-UAC CCU GUA GAA CCG
AAU UUG UG-3′, antisense: 3′-CAA AUU CGG UUC
UAC AGG GUA UU-5′) eukaryotic expression plasmid
was obtained from GenePharma Company (Shanghai,
China). An antisense (anti-miR-10b; sequence: 5′-CAC
AAA UUC GGU UCU ACA GGG UA-3′) was used to
inhibit miR-10b expression. A scrambled RNA duplex
(sense: 5′-UUC UCC GAA CGU GUC ACG UTT-3′,
antisense: 5′-ACG UGA CAC GUU CGG AGA ATT-3′)
expression plasmid was used as the control. The day be-
fore transfection, A549 cells were seeded in antibiotic-free
medium. Transfections were carried out using Lipofecta-
mine 2000 (Invitrogen) in accordance with the manufac-
turer’s instructions. To monitor transfection efficiency,
successfully transfected cells were observed with a fluores-
cence microscope.
qRT-PCR
Total RNA, including miRNA, was isolated with TRIzol
Reagent (Invitrogen) according to the manufacturer’s in-
structions. Expression of hsa-miR-10b was analyzed with
the miScript system (Qiagen, Venlo, The Netherlands),
which consists of the miScript RT Kit, miScript Primer
Assay, and miScript SYBR Green PCR Kit, according to
the protocol provided by the company. Small nuclear
RNA U6 was used for normalization; cDNA was synthe-
sized using Moloney Murine Leukemia Virus ReverseTranscriptase (Takara, Dalian, China) as described by
the manufacturer. Primers used were as follows: miR-
10b forward primer: 5′- GGA TAC CCT GTA GAA
CCG AA -3′ and reverse primer: 5′-CAG TGC GTG
TCG TGG AGT-3′. U6 sense: 5′-CTC GCT TCG GCA
GCA CA-3′ and reverse: 5′-AAC GCT TCA CGA ATT
TGC GT-3′. The PCR reaction was conducted at 95°C
for 30 seconds, followed by 40 cycles of 95°C for 5
seconds and 60°C for 34 seconds on the ABI Prism 7700
Sequence Detector (Applied Biosystems, Carlsbad, CA,
USA). All of the reactions were run in triplicate. The
comparative method (ΔΔCT) was used for relative quanti-
fication of gene expression to determine miR-10b mRNA
expression levels.
Wound healing assay
Cells transfected with miR-10b, negative control, and anti-
miR-10b were plated in 35 mm dishes. When cells grew
to confluence, a line was traced with a pipette tip. A549
cells were then washed with serum-free medium and incu-
bated with RPMI 1640. The wound was photographed at
0, 24, 48, and 72 hours.
Annexin-V-fluorescein isothiocyanate (FITC)
apoptosis assay
Cells were collected after miR-10b transfection for 72 hours,
and the translocation of phosphatidylserine in treated cells
was detected using the Annexin-V-FLUOS Staining Kit
(Roche Applied Science, Mannheim, Germany). Briefly,
cells were suspended in 500 mL of binding buffer and incu-
bated at room temperature in the dark for 15 minutes after
being labeled with 5 mL of Annexin-V-fluorescein isothio-
cyanate (FITC) and 5 mL of propidium iodide (PI). The
stained cells were then analyzed by flow cytometry.
Cell proliferation assay and cell cycle analysis
Cell viability was assessed by Cell Counting Kit (CCK)-8
kit (Tongren, Shanghai, China). Briefly, 0.5 × 104 cells
were seeded in each 96-well plate, transfected with the
indicated miR-10b, and further incubated for 24, 48, and
72 hours, respectively. Approximately 10 mL CCK-8 re-
agent was added to each well at 1 hour before the endpoint
of incubation. The optical density (OD) 450 nm values in
each well were determined by a microplate reader.
For cell cycle analysis, cells were fixed, stained with PI,
and examined with a fluorescence-activated cell sorting
(FACS) flow cytometer (Beckman Coulter, Pasadena, CA,
USA). DNA histograms were analyzed using MultiCycle
software (Phoneix Flow Systems, San Diego, CA, USA).
Invasion assay
Cell invasion was analyzed with uncoated transwell cell cul-
ture chambers (8 μm pore size) (Yu Kangning, Shanghai,
China). Briefly, 48 hours after transfection, cells were
Figure 1 miR-10b expression on A549 and H1299 cells. (A) Fluorescence photomicrographs of A549 cells infected by miR-10b at a multiplicity
of transfection of 10. Images were taken 72 hours after infection. Scare bar = 100 μm. (B) miR-10b was subjected to real-time PCR analysis for
miR-10b and U6 expression levels. Ectopic expression of miR-10b on A549 and H1299 cells was analyzed by qRT-PCR. Asterisks indicate significant
difference when compared with control (P <0.05). miR-10b, microRNA-10b.
Figure 2 miR-10b promotes proliferation of A549 and H1299 cell lines. (A) A549 cell proliferation significantly increased after miR-10b expression.
Asterisks indicate significance compared with control (P <0.05). (B) H1299 cell proliferation significantly increased after miR-10b expression. Asterisks indicate
significance compared with control (P <0.05). (C) Cell cycle distributions of A549 cells transfected with the miR-10b. miR-10b, microRNA-10b.
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suspension (4 × 104 cells) was added to the upper chamber.
Medium containing 10% serum as a chemoattractant was
added to the bottom wells of the 24-well chamber. For the
screen, the cells that did not invade after 24 hours were re-
moved from the upper face of the filters by scrubbing with
a cotton swab, after which the membrane was fixed with
4% formaldehyde for 10 minutes at room temperature and
stained with 0.5% crystal violet for 10 minutes. Finally, inva-
sion cells were counted from ten different fields of each fil-
ter. Experiments were repeated in triplicate.Figure 3 miR-10b suppresses the invasion of A549 and H1299 cells. (
to Matrigel migration assays. The migrated cells were stained with crystal v
and analyzed. Data shown are mean ± SD of triplicate measurements. *P <
mean ± SD of triplicate measurements. *P <0.05. miR-10b, microRNA-10b.Western blot analysis
Immunoblotting was performed to detect the expression
of KLF4 in A549 cell lines. Cultured or transfected cells
were lysed in radioimmunoprecipitation assay (RIPA)
buffer with 1% phenylmethanesulfonyl fluoride (PMSF).
Protein was loaded onto an SDS-PAGE mini-gel and
transferred onto polyvinylidene difluoride (PVDF) mem-
brane. The blots were probed with 1:1,000 diluted rabbit
polyclonal KLF4 antibody (Abcam, Cambridge, UK) at 4°C
overnight and subsequently incubated with horseradish
peroxidase (HRP)-conjugated secondary antibody (1:5,000).A) A549 cells transfected with the miR-10b or inhibitor were subjected
iolet for 30 minutes. Scare bar = 100 μm. (B) A549 cells were counted
0.05. (C) H1299 cell migration assays were performed. Data shown are
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Billerica, MA, USA). GAPDH was used as an endogenous
protein for normalization.
Statistical analysis
All data from three independent experiments were ex-
pressed as mean ± SD and processed using SPSS 17.0
statistical software (IBM, Armonk, NY, USA). The dif-
ference was estimated by Student’s t-test or one-way
ANOVA. A value of P <0.05 was considered to be statis-
tically significant.
Results
miR-10b expression in A549 cells
To further study the biological role of miR-10b in lung can-
cer progression, we transfected A549 and H1299 cells with
GFP-labeled plasmids carrying miR-10b. We routinely ob-
served a highly efficient infection (> 90%) 72 hours after
transfection at multiplicity of transfection of 10 through
estimating EGFP expression under a fluorescent micro-
scope (Figure 1A). We performed SYBR green quantitative
PCR analysis to detect the expression levels of miR-10b in
A549 and H1299 cells. The level of miR-10b expression in
cultures of A549 cells was greater than the control group
(Figure 1B).
miR-10b inhibition leads to increase of A549 cell growth
Understanding the regulation of cell proliferation will be
critical for the development of new and more successful
therapies for preventing and treating cancer, and for the
screening of new anticancer drugs. Therefore, the rapid
and accurate assessment of cell proliferation is an im-
portant requirement in many experimental situationsFigure 4 miR-10b promotes the migration and invasion of A549 cells
subjected to wound healing assays and images were taken at 0, 24, 48, andinvolving in vitro and in vivo studies. Viability assays were
used as a further study to investigate the effect of miR-10b
on proliferation of A549 cells. The results of this assay
showed that miR-10b could enhance the A549 cell growth
remarkably (Figure 2A) and also in H1299 cells (Figure 2B),
and provides evidence that miR-10b plays a key role in
promoting the development of lung cancer.
To test whether miR-10b affected the behavior of A549
cells, we detected the cell cycle of A549 cells with
miR-10b or anti-miR-10b transfection. Compared with
the cells transfected with the negative control miRNA, the
proliferation of A549 cells transfected with anti-miR-10b
was significantly decreased (Figure 2C), while A549 cell
growth increased in miR-10b transfection, indicating that
miR-10b may increase A549 cell proliferation.MiR-10b promotes the invasiveness of A549 cells
We investigated the role of miR-10b in the invasiveness
of A549 and H1299 cells, which is an important aspect
of malignant progression and metastasis. MiR-10b was
significantly overexpressed after transfection of the
miR-10b. As shown in Figure 3, the number of invading
A549 and H1299 cells transfected with the miR-10b was
greater than the control group (P < 0.05). These findings
suggest that miR-10b expression may play a specific role
in the invasiveness of A549 cells.
We further investigated the effects of miR-10b on A549
cell migration, two essential steps for malignant progres-
sion and metastasis. A549 cells transfected with the
miR-10b or anti-miR-10b were applied to wound healing
assays. The results showed that miR-10b significantly in-
creased the migration of A549 cells, whereas anti-miR-10b
decreased the migration of A549 cells (Figure 4).. A549 cells were transfected with miR-10b or inhibitor. Cells were
72 hours. Scare bar = 100 μm. miR-10b, microRNA-10b.
Figure 5 Apoptosis assay. After transfection with miR-10b overexpression vector for 48 hours, Annexin-V-FITC and PI co-staining were used for
flow cytometric analysis. FITC, fluorescein isothiocyanate; miR-10b, microRNA-10b; PI, propidium iodide.
Figure 6 Prediction of miR-10b target gene. KLF4 protein levels were detected by Western blot assay. The expression of KLF4 was increased
by miR-10b when compared with the control and anti-miR-10b. KLF4, Krüppel-like factor 4; miR-10b, microRNA-10b.
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To further confirm the important role of miR-10b in
A549 cells, we examined the effects of miR-10b over-
expression on apoptosis induced by this miRNA. After
successful transfection of miR-10b and anti-miR-10b, we
found that overexpression of miR-10b did not signifi-
cantly inhibit the early and late apoptosis, and total
apoptotic cell death in A549 cells (Figure 5). These re-
sults suggest that overexpression of miR-10b could pro-
mote A549 cell survival.
Examination of the targeting of miR-10b
Western blot analysis showed that the KLF4 protein ex-
pression levels were significantly increased after miR-10b
transfection; in contrast, the anti-miR-10b transfection ef-
fectively downregulated the KLF4 protein expression levels
as examined by western blot analysis (Figure 6), which in-
dicated that the KLF4 gene was not the indirect target of
miR-10b.
Discussion
In recent years, molecular genetic studies have shown
that abnormalities in non-coding miRNAs represent the
most recent class of epigenetic mechanisms, which can
also contribute to the different steps of tumor develop-
ment by regulating genes that control cellular processes
such as the cell cycle and apoptosis. Recently, several
studies have shed light on the importance of miRNAs in
cancer invasion and metastasis. Upregulation of miR-
10b expression has been detected in metastatic breast
cancer, esophageal cancer, malignant glioma, pancreatic
cancer, and others [21-24], and miR-10b can positively
regulate migration and invasion in both breast cancer
and esophageal cancer cell lines [25-29]. Moreover, miR-
10b also has a role in regulating angiogenesis in glioma-
genesis [20]. However, the biological consequences of
miR-10b overexpression have not been characterized in
lung cancer. In this study, we investigated the role and
functional target of miR-10b in A549 cells.
We showed that transfected miR-10b was associated
with growth promotion and invasiveness of A549 cells,
and these findings are consistent with a previous study.
Ma et al. showed that miR-10b decreased the expression
of HOXD10, resulting in increased expression of RhoC
[9]. In addition, Sasayama et al. showed an association
between miR-10b and uPAR [15], which is considered to
be one of the downstream targets of HOXD10. We did
not detect HOXD10 expression in lung cancer, and there
have been no previous reports regarding HOXD10 expres-
sion and lung cancer. Therefore, there may be no relation-
ship between HOXD10 and uPAR/RhoC expression in
lung cancer, although uPAR and RhoC were reported to
be correlated with the invasiveness of lung cancer. Identi-
fication of putative miRNA targets is important for acomplete understanding of the specific functions of
miRNAs. In this study, we identified KLF4 as an indirect
target of miR-10b, and demonstrated that upregulation of
miR-110b significantly increases KLF4 expression at pro-
tein level in NSCLC cells. Other mechanisms may affect
the invasiveness of lung cancer cells, but since only func-
tional analysis was studied, further investigation such as
loss of function of miR-10b will be needed in the future.
Conclusions
In conclusion, we found that miR-10b is a tumor enhan-
cer in NSCLC. Thus, miR-10b may represent a potential
therapeutic target for NSCLC intervention.
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